MEDI7510 for Respiratory Syncytial Virus Advances to Phase

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS(TM) Discovery Platform

SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ ), a clinical-stage immunotherapy company focused on oncology, today highlighted the application of its GLAAS TM discovery platform in MedImmune's Phase 2 clinical trial of MEDI7510. MEDI7510 is an investigational agent for the prevention of respiratory syncytial virus (RSV) under development by MedImmune, the global biologics research and development arm of AstraZeneca. MEDI7510 is composed of MedImmune's RSV sF antigen plus GLA, a synthetic molecule licensed from Immune Design's GLAAS discovery platform.

This stems from an existing agreement in which Immune Design granted MedImmune an exclusive license to use the GLAAS platform to develop and commercialize vaccines in two different infectious disease indications, one of which is RSV.

The Phase 2, double-blind, randomized, placebo-controlled study ( NCT02508194 ) is designed to assess the efficacy of MEDI7510 for the prevention of acute RSV-associated respiratory illness in older adults. The study will also evaluate the safety and immunogenicity of MEDI7510 or placebo and immune response to MEDI7510 in Season 1 and Season 2. The trial is expected to enroll approximately 1,900 adult subjects, 60 years or older, globally.

"It's rewarding to see MEDI7510 continue to advance through clinical development," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "The field of RSV vaccines has been challenging. A small molecule that activates TLR4 and drives a Th1-type of immune response should be ideally suited to overcome the Th2-prone activity of RSV antigens, which can result in severe lung pathology. We are hopeful of the potential benefit MEDI7510 may bring to older adults."

ABOUT RSV

Respiratory Syncytial Virus (RSV) is a common virus that can cause upper and lower respiratory infections, including colds, bronchitis and pneumonia. RSV is increasingly recognized as an important cause of respiratory infections in adults, particularly affecting the elderly, immunocompromised, and those with underlying chronic cardiopulmonary disease. For example, RSV is estimated to infect 5%–10% of nursing home residents per year, with rates of pneumonia and death of 10%–20% and 2%–5%, respectively (Falsy, Clin Microbiol Rev 2000). Currently no vaccine is available for RSV and induction of a Th1 type immune response is viewed as an important feature for any successful vaccine candidate.

About GLAAS

Immune Design's GLAAS platform works in vivo and is based on a small synthetic molecule called GLA, which stands for glucopyranosyl lipid A. GLA selectively binds to the TLR4 receptor and causes potent activation of dendritic cells (DCs). When GLA is accompanied by an antigen and injected into a patient, the combination is taken up by DCs and leads to the production and expansion of immune cells called CD4 T helper lymphocytes. These CD4 cells play a key role in boosting the anti-tumor immune response by expanding the number and function of existing CTLs that are specific to the same antigen and providing help to other immune cells, including B lymphocytes that are the precursor to antibodies and natural killer cells that are also important in the overall immune response. In addition to infectious diseases, Immune Design believes that GLAAS product candidates have the potential to target multiple types of cancer and allergic diseases.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary focus of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex TM and GLAAS TM , the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively.  Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com .

Forward Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of initiation, progress, scope and outcome of clinical trials for Immune Design's product candidates and the reporting of clinical data regarding Immune Design's product candidates. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact for Immune Design: Media Contact Julie Rathbun Rathbun Communications 206.769.9219 Investor Contact Shari Annes Annes Associates 650-888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 118

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 112

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 107

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 94

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 9

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 40

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 0

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $1000 into $3500: The Cboe Investment Journey

Updated Category News Views 346

A Decade of Growth: The Journey of Cboe Global Markets Cboe Global Markets (NASDAQ: CBOE) has showcased remarkable performance over the last ten years. With an average annual return of 13.08%, the stock has consistently outpaced the market by 1.88%. As of now, the company boasts a significant market capitalization of $22.24 billion, reflecting its robust position in the...

Continue Reading
New Jersey's Hemp Law Blocked by Judge: A Look into the Future

Updated Category News Views 227

New Jersey's Hemp Law Blocked by Judge: A Look into the Future A recent court ruling has caused a significant shift in New Jersey’s hemp regulation landscape. A federal judge has ruled parts of the Revised New Jersey Hemp Law unconstitutional, asserting that certain provisions unfairly restrict interstate commerce and counter federal guidelines. This decision marks a...

Continue Reading
Kirkland's Fights Through Challenges with Strategic Plans

Updated Category News Views 175

Kirkland's Reports Mixed Results for Q2 Amid Strategic Changes Kirkland's (NASDAQ: KIRK), a well-known specialty retailer specializing in home décor and gifts, has released its financial results for the second quarter. The company experienced a 1.7% decline in total comparable sales, largely driven by a significant 10.6% drop in e-commerce sales. On a more positive note,...

Continue Reading
noco-noco Inc Updates Timeline for Share Consolidation Strategy

Updated Category News Views 89

noco-noco Inc Announces New Timeline for Reverse Stock Split Recently, noco-noco Inc. has made significant updates regarding its plans for a reverse stock split, a necessary step to align with Nasdaq’s minimum bid price requirement. This decision follows an unforeseen delay that would impede their initial plan set for implementation. Background on the Reverse Stock...

Continue Reading
Strong Performance of Mexican Stocks Fuels Investor Confidence

Updated Category News Views 187

Mexican Stock Market Sees Positive Gains Recently, investors in the Mexican stock market experienced an uplift as stocks showed significant gains. The market closed higher, indicating a robust performance across various sectors. This surge was primarily driven by strong performances in key areas such as Industrials, Consumer Goods, and Consumer Staples, all contributing...

Continue Reading